Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)

Trial Profile

3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2018

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Aug 2018 Planned End Date changed from 27 Jul 2018 to 20 Jan 2019.
    • 13 Aug 2018 Planned primary completion date changed from 20 Jul 2018 to 20 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top